Keros Therapeutics, Inc.
KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopeā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.11
Price+0.40%
$0.04
1Y
Price
Market Cap
$323.500m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-6350.1%
EBITDA Margin-6459.9%
Net Profit Margin-981.5%
Free Cash Flow Margin-6350.1%
EBITDA Margin-6459.9%
Net Profit Margin-981.5%
Free Cash Flow MarginRevenue
$33.182m
-86.4%
1y CAGR+2979.9%
3y CAGR+2234.9%
5y CAGREarnings
-$85.145m
-197.8%
1y CAGR-24.6%
3y CAGR-30.0%
5y CAGREPS
-$1.95
-184.8%
1y CAGR-11.6%
3y CAGR-15.1%
5y CAGRBook Value
$285.630m
$312.293m
Assets$26.663m
Liabilities$16.311m
DebtDebt to Assets
5.2%
-0.2x
Debt to EBITDAFree Cash Flow
-$58.254m
-155.0%
1y CAGR-6.0%
3y CAGR-24.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company